Recombinant Humanized (from mouse) antibody to Human PCSK9. Bococizumab (codenamed RN316)is a monoclonal antibody against PCSK9 designed to reduce LDL cholesterol
Figure 1 Effect of Antidrug Antibodies on the Durability of Low-Density Lipoprotein (LDL) Cholesterol Lowering and on Plasma Bococizumab and PCSK9 Levels.
Panel A shows the effect of generalized antidrug antibodies (ADAs) on LDL cholesterol levels among the patients who received placebo and among those who received bococizumab, according to whether the patients were ADA-negative throughout the trial, had ADA titers in the lowest two thirds of maximum titers (<1:1176) during follow-up, had ADA titers in the highest third of titers (≥1:1176) during follow-up, or were in the subgroup with ADA titers in the top 10% (≥1:5674). The light blue bars indicate prevalent rates of antibodies at each time point, and the dark blue bars the cumulative incidence of antibody positivity during follow-up. Panel B shows plasma bococizumab levels and Panel C total plasma proprotein convertase subtilisin–kexin type 9 (PCSK9) levels over time, according to the ADA titer. Panel D shows the effect of the neutralizing antibody (NAb) titer on LDL cholesterol levels.
Ridker, P. M., Tardif, J. C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W.,... & Revkin, J. (2017). Lipid-reduction variability and antidrug-antibody formation with bococizumab. New England Journal of Medicine, 376(16), 1517-1526.
Figure 2 Variability in the Reduction in LDL Cholesterol Levels, According to the Presence or Absence of Antidrug Antibodies (ADAs).
Waterfall plots for individual patients who received bococizumab show the percent change from baseline in LDL cholesterol levels at 12 weeks (Panel A) and at 52 weeks among the patients in whom antidrug antibodies developed (Panel B) and among those in whom antidrug antibodies did not develop (Panel C). Data are limited to the patients who reported having received bococizumab in the 21 days before the measurement of LDL cholesterol.
Ridker, P. M., Tardif, J. C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W.,... & Revkin, J. (2017). Lipid-reduction variability and antidrug-antibody formation with bococizumab. New England Journal of Medicine, 376(16), 1517-1526.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Bococizumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized (from mouse) antibody to Human PCSK9. Bococizumab (codenamed RN316)is a monoclonal antibody against PCSK9 designed to reduce LDL cholesterol
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-758 | Anti-PCSK9 Recombinant Antibody (Lodelcizumab) | ELISA, FC, IP, FuncS, IF, Neut, ICC | IgG1 - kappa |
TAB-0020CL | Anti-Human PCSK9 Recombinant Antibody (LPD1282/LPD1462 {i.e., antibody 1 F11)) | LDL-c uptake assay | Humanized Antibody |
TAB-0957CL | Anti-Human PCSK9 Recombinant Antibody (h7F8) | ELISA | Humanized antibody |
TAB-0958CL | Anti-Human PCSK9 Recombinant Antibody (h7F8ml2) | ELISA | Humanized antibody |
TAB-0020CL-F(E) | Anti-Human PCSK9 Recombinant Antibody Fab Fragment (LPD1282/LPD1462 {i.e., antibody 1 F11)) | LDL-c uptake assay | Humanized Antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
PABL-294 | Human Anti-PCSK9 Recombinant Antibody (clone mAb1) | WB, Block, FuncS | Human IgG |
PABC-196 | Human Anti-PCSK9 Recombinant Antibody (clone J16) | IF, IP, WB, ELISA | Human IgG |
HPAB-0051-FY | Human Anti-PCSK9 Recombinant Antibody (HPAB-0051-FY) | Inhib, ELISA | Human IgG2, κ |
HPAB-0141-FY | Human Anti-PCSK9 Recombinant Antibody (clone YW508.20.33) | FuncS, In vivo | Human IgG1 |
HPAB-0152-FY | Mouse Anti-PCSK9 Recombinant Antibody (HPAB-0152-FY) | ELISA | Mouse IgG, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
PFBL-670 | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (PFBL-670) | WB, FuncS | Human Fab |
PFBL-671 | Mouse Anti-PCSK9 Recombinant Antibody (clone mAb J16); Fab Fragment | WB, ELISA, FuncS | Mouse Fab |
PFBL-672 | Human Anti-PCSK9 Recombinant Antibody (clone CBL36Q); Fab Fragment | ELISA, WB | Human Fab |
PSBC-196 | Human Anti-PCSK9 Recombinant Antibody (clone J16); scFv Fragment | ELISA | Human scFv |
HPAB-0234-YC-F(E) | Mouse Anti-PCSK9 Recombinant Antibody; Fab Fragment (HPAB-0234-YC-F(E)) | ELISA, FuncS | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0956CL | Anti-Human PCSK9 Recombinant Antibody (m7F8) | ELISA | |
TAB-0960CL | Anti-Human PCSK9 Recombinant Antibody (Ab1) | ELISA | Rabbit mAb |
TAB-0956CL-S(P) | Anti-Human PCSK9 Recombinant Antibody scFv Fragment (m7F8) | ELISA | |
TAB-0960CL-S(P) | Anti-Human PCSK9 Recombinant Antibody scFv Fragment (Ab1) | ELISA | Rabbit mAb |
TAB-0956CL-F(E) | Anti-Human PCSK9 Recombinant Antibody Fab Fragment (m7F8) | ELISA |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0959CL | Human Anti-PCSK9 Recombinant Antibody (TAB-0959CL) | ELISA, FC | Human antibody |
TAB-0959CL-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (TAB-0959CL-S(P)) | ELISA, FC | Human scFv |
TAB-0953CL-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (TAB-0953CL-F(E)) | ELISA | Human Fab |
TAB-0954CL-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (TAB-0954CL-F(E)) | WB | Human Fab |
TAB-0959CL-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (TAB-0959CL-F(E)) | ELISA, FC | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0080CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (PKE2) | FuncS, Inhib, FC, WB | Single domain antibody |
TAB-0081CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (PKF8) | FuncS, Inhib, FC, WB | Single domain antibody |
TAB-0082CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (PKG1) | FuncS, Inhib, FC, WB | Single domain antibody |
TAB-0083CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (P1.70) | FuncS, Inhib, FC, WB | Single domain antibody |
TAB-0084CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (PKE1) | FuncS, Inhib, FC, WB | Single domain antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1826CQ | Recombinant Human Anti-PCSK9 Antibody, Unconjugated | Neut | IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-2618 | Hi-Affi™ Recombinant Rabbit Anti-PCSK9 Monoclonal Antibody (DS2618AB) | WB | IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-758 | Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Lodelcizumab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
AFC-TAB-H10 | Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Bococizumab), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS | ADCC enhanced antibody |
AFC-TAB-H59 | Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Ralpancizumab), ADCC Enhanced | Neut, ELISA, IF, IP, FuncS, FC | ADCC enhanced antibody |
AFC-TAB-H31 | Afuco™ Anti-PCSK9 Recombinant Antibody (AFC-TAB-H31), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | Human IgG1, λ |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-3139LY-S(P) | Human Anti-PCSK9 Recombinant Antibody (clone S3A12); scfv Fragment | ELISA, Inhib | Human scfv |
HPAB-0479-YJ-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (HPAB-0479-YJ-S(P)) | ELISA, Inhib, FuncS | Human scFv |
HPAB-0480-YJ-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (HPAB-0480-YJ-S(P)) | ELISA, Inhib, FuncS | Human scFv |
HPAB-AP783-YC-S(P) | Mouse Anti-PCSK9 Recombinant Antibody; scFv Fragment (HPAB-AP783-YC-S(P)) | ELISA, WB | Mouse scFv |
HPAB-0724YY-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (HPAB-0724YY-S(P)) | ELISA | Human scFv |
There are currently no Customer reviews or questions for TAB-H10. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.